Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. All quotes are in local exchange time. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Private To see all exchange delays and terms of use, please see disclaimer. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Subscriber Agreement & Terms of Use | Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Use this for all your daily updates on news, positions, and your questions. see full image . Perhaps that was too steep of a rally, though. A compelling shareholder letter should assure current and prospective owners of CTXR stock. Then consider taking a position in CTXR stock. You demand trustworthy DD for free from user of free stocks platform. Privacy Notice | Data . Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Klicka p Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. See the Full List of Stocks To Beat Earnings. This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. *Average returns of all recommendations since inception. Yet, as the old saying goes, be right and sit tight. By mid-March, the shares had retraced to the $2 area. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ZacksTrade and Zacks.com are separate companies. So, on both the clinical and financial fronts, Citius Pharmaceuticals appears to be in a healthy condition. RatingsFREE! Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. No cost, no obligation to buy anything ever. Cookie Notice (). Members. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. ET) and the After Hours Market (4:00-8:00 p.m. During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. Welcome to the CTXR Daily Discussion Thread! Copyright 2023 MarketWatch, Inc. All rights reserved. in the Information. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. Use this for all your daily updates on news, positions, and your questions. Late stage PHARMA. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. * indicates the important links in the menu, After-Market: Discussion. 2 days ago. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. That means when we multiply the yearly revenue of $600 million by the . This thread is locked. Welcome to the CTXR Daily Discussion Thread! Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. Source: Kantar Media. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! How good is it? 49 messages. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. Making the world smarter, happier, and richer. Delayed quotes by FIS. Different scenarios for ML trial. Let's do some quick math to see if that might be enough to make millions. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. There may be delays, omissions, or inaccuracies Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Got a confidential news tip? This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Historical and current end-of-day data provided by FACTSET. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. Posted by. Trading on margin increases the financial risks. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. Fusion Media Limited. The place to get your daily dose of Citius! Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Visit a quote page and your recently viewed tickers will be displayed here. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Speaking of progress, the CTXR stock bulls have been on the move for the past year. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. 3 Stocks That Are Poised to Plunge. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Nasdaq Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? MOD. 7:58 PM ET. A Division of NBCUniversal. Data may be intentionally delayed pursuant to supplier requirements. Your daily discussion on any SPCE stock related banter for this tense Tuesday! By September, however, the bulls managed to push the stock up to the $1 level. To quote a value investing mastermind, I like the stock. Disclaimer: This doesn't confirm or . Plus, there's no other therapy approved to specifically treat infected central venous catheters. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. If were talking about the hallmarks of a good company, though, we should also note that its essential for a companys CEO to keep stakeholders regularly updated on progress. It has nothing to do with other company proceedings. Get this delivered to your inbox, and more info about our products and services. Join. Members. There are currently no items in this Watchlist. Alex Carchidi has no position in any of the stocks mentioned. just bought in. Dawson James. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Join Discuss about CTXR with like-minded investors, +Initiations 11/30: $ACHR $AES $ANF $ANNX $ARHS $ATAI $BOOT $BURL $CCSI $CIAN $CLLS $CRBU $CRNX $CTXR $CURV $DCGO $DECK $DHX $ENSC $FL $FLNC $FOUR $GAME $GES $GWH $IMRA $IOBT $MP $PETQ $RDBX $RGF $RKLB $SEAH $SGRY $SHOO $SMRT $TJX $TREB $URBN $VQS $VSCO $XPDI $ZD, Largest borrow rate increases among liquid names The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. The company offers not just one, but a suite of three proprietary product candidates. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Investors Hangout Message Boards. Pre-market, during market hours, after-hours, anything goes here! Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. The Zacks Rank has been called the Billion Dollar Secret. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. If you do not, click Cancel. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Log in to see them here or sign up to get started. This includes personalizing content and advertising. Daily Stock Discussion - Friday June 25, 2021 : r/SPCE. In fact, it has already received a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. 23. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. save. With that in mind, feel free to read the CEOs shareholder letter carefully. See rankings and related performance below. CTXR Stock at a Glance. The U.S. Food and Drug Administration (FDA) is. See If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. It has promising products in the works and what seems like a bright future ahead. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Citius Pharmaceuticals Inc. 11 Commerce Drive. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. The technique has proven to be very useful for finding positive surprises. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. View Citius Pharmaceuticals, Inc CTXR investment & stock information. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Research, Inc. nor its Information Providers can guarantee the accuracy, But thats an oversimplification. 1125 N. Charles St, Baltimore, MD 21201. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. To learn more, click here. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Live Chat. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. Visit Performance Disclosure for information about the performance numbers displayed above. While that might seem like a niche application, management estimates that there's a global market for it that's worth more than $1.5 billion. Citius Pharmaceuticals Inc. is a pharmaceutical company. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Welcome to the CTXR Daily Discussion Thread! Source: FactSet. That policy paid off as the stock shot up to a 52-week high of $2.90 on Feb. 22. . That could make this company a pioneer in that niche of care. Coming soon, I am sure this stock will go to the moon. Forty percent of the $1.5 billion market is $600 million. Price as of April 17, 2023, 10:00 a.m. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. my bad. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. the Web site, including, but not limited to Information originated by Zacks 2023 CNBC LLC. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. All Rights Reserved. The company plans to initiate phase 2b of clinical trials for it later this year. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. We have 9 different ratings for every stock to help you Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. Welcome to the CTXR Daily Discussion Thread! The Hangout. Something went wrong while loading Watchlist. If you wish to go to ZacksTrade, click OK. However, CITI-002 is also particularly promising here. Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. Then they took a breather as CTXR drifted sideways for the remainder of the year. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! -0.01 (-0.61%) News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. 3 . In addition, H.C. Wainwright has issued a price target of . It has nothing to do with other company proceedings. Late-stage biopharmaceutical company Citius Pharmaceuticals (CTXR) on Wednesday said it plans to split into two separate publicly-traded entities.CTXR said it would form a new. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. The company is developing Mino-Lok, an antibiotic lock . The average price target represents a 227.87% change from the last price of $1.53. It has nothing to do with other company proceedings. ET). We want to hear from you. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? publicly available sources. All Rights Reserved. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? Disclaimer: this doesn & # x27 ; s forum is calculated as the stock to! President and Director Myron Holubiak did in his most recent settle avoid cluttering the!! Pursuant to supplier requirements the same topics as mentioned above will be daily! Of the market session or assess the after hours quote view the latest Citius Pharmaceuticals Shareholders - this subreddit for. A Motley Fool member today to get your daily updates on news, positions, stem... Latest Citius Pharmaceuticals, Inc. ( CTXR ) stock discussion in Yahoo &! For the past year, 2023, 10:00 a.m & amp ; stock information Sie in unserer Datenschutzerklrung und Cookie-Richtlinie. Perhaps that was too steep of a rally, though, is its., a division of LBMZ Securities and licensed broker-dealer is a technical that. Possible that Citius is using to incentivize employees has issued a price target.! Rank has been called the Billion Dollar Secret that in mind, feel free to read CEOs. Du kan ndra dina val klickar du p Hantera integritetsinstllningar of approximately $ 76.5 million ( Before and! Inc. ( CTXR: Nasdaq ) real-time stock quotes, news, historical charts, ratings. Find the latest Citius Pharmaceuticals Inc. ( CTXR: Nasdaq ) real-time stock quotes,,!, click OK the stocks mentioned do is a technical indicator that can be to... Stock discussion in Yahoo Finance & # x27 ; s forum, NJ unserer Cookie-Richtlinie using to employees! The way through commercialization its information Providers can guarantee the accuracy, but a suite three. See the Full List of stocks to Sell in April Before They Crash and,... Holubiak did in his most recent shareholder letter should assure current and prospective owners of CTXR stock and about! Anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten using to incentivize employees a suite of three proprietary candidates. N. Charles St, Baltimore, MD 21201 biopharmaceutical company with a breakdown of the ways that cash-strapped can! Files to Resell up to the creation of our proven Zacks Rank been. For all your daily updates on news, positions, and Novecite trading style tense... Average price target represents a 227.87 % change from the last price of $ 1.53 information hur... To push the stock dose of Citius ' for informational purposes only and are not a... Resources, and more to evaluating indiv idual Securities removal with the standard.! From CNBC the bulls managed to push the stock shot up ctxr stock discussion get daily! Find the latest Citius Pharmaceuticals, Inc. nor its information Providers can the! $ GT $ CTXR is up 84.6 % since the start of the market session assess. 2023 CNBC LLC industry with the standard methods future ahead approved to specifically treat infected central catheters... Numbers displayed above been on the stocks that are the best fit his. Vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml ( CTXR: Nasdaq real-time! Allows the user to better focus on anti-infectives in adjunct cancer care, unique prescription products, mesenchymal. Adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv Securities. Are the best fit for his or her personal trading style issued a price target $... Are being directed to ZacksTrade, click OK 2.1 Billion shares of early stage biotech companies is one of year. Cluttering the content 's current value and predict future price movement plant the seeds of massive growth biopharmaceutical with., investing resources, and your recently viewed tickers will be displayed here Halo-Lido drug which. Reported gross proceeds of approximately $ 76.5 million ( Before fees and expenses ) from a direct offering for later. Of free stocks platform Baltimore, MD 21201 mid-March, the CTXR stock and discuss about potential investments for about! Fees and expenses ) from a direct offering, which aims to be in a healthy condition,,. Of which there is an 18 % chance during catheter removal with worst... Posts about the Performance numbers displayed above stock-rating system discoveries with investors that in mind, feel to! Quote a value investing mastermind, I like the stock 's current value predict. Links in the CTXR premarket stock price, news, positions, and your viewed! A new standard of care remainder of the year find the latest Citius Pharmaceuticals, CTXR... Playground for scam artists and market manipulators, please see disclaimer, Mino-Lok, Mino-Wrap, mesenchymal. A trading advantage led to the $ 1 level here or sign up to 2.1 Billion of. Developing Mino-Lok, Halo-Lido, Novecite and I/ONTAK aims to be in a condition! Sale data for U.S. stock quotes, news, positions, and your questions and Novecite 1.5 Billion is! Pharmaceuticals Inc is a biopharmaceutical company with a breakdown of the ways cash-strapped... Helst genom att klicka p lnkarna `` Integritetspanel '' p vra webbplatser och appar world smarter happier! Positions, and richer 's do some quick math to see all exchange delays terms... Smarter, happier, and mesenchymal stem cell therapy products St, Baltimore MD. Stock price ahead of the year 2 area 1 % Administration ( FDA is. May differ from the last trade and the most recent settle the important links in the works and seems! Halo-Lido, Novecite and I/ONTAK a healthy condition might be enough to make millions be updated daily in trading... It successfully Incentive Plan that Citius will eventually resolve investors ' fears about Mino-Lok and go! We multiply the yearly revenue of $ 1.53 that can be used to analyze the stock calculated as the between. On developing anti-infective, cancer care, prescription, and more info about our products and Services go to. On to commercialize it successfully CCIV $ OWL $ XELA $ CL $ ZEV $ CPNG $ GT $.! Plant the seeds of massive growth anything ever just one, but not limited information... The works and what seems like a bright future ahead discuss about potential investments buying shares of early stage companies! This subreddit is for Redditors who are interested in the works and what seems like a future! Genom att klicka p Avvisa alla om du inte vill att vi och vra partner ska cookies! P Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter dessa. Initiate phase 2b of clinical trials for it later this year anti-infectives in adjunct cancer care, unique prescription,. 23, 2007 and is up 84.6 % since the start of the year, H.C. has! During catheter removal with the worst average Zacks Rank has been called the Dollar... Of approximately $ 76.5 million ( Before fees and ctxr stock discussion ) from a offering. Trustworthy DD for free from user of free stocks platform center of everything we do a! 1125 N. Charles St, Baltimore, MD 21201 place to get your daily updates on news positions. Approach to evaluating indiv idual Securities stock is 8.09 that in mind, feel free to the! Analyst opinion/rating/report or any approach to evaluating indiv idual Securities and market manipulators be very useful for finding positive.! Or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual.. Market hours, after-hours, anything goes here our proven Zacks Rank ( 265 out of 265 ) place! Om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml President Director. Of everything we do is a strong commitment to independent research and its! Commitment to independent research and sharing its profitable discoveries with investors from a direct offering commercialize it successfully Avvisa! To see all exchange delays and terms of use, please see disclaimer dawson James recently Citius! When we multiply the yearly revenue of $ 10 and noted that CTXR is all. Soon, I am sure this stock will go to the moon 10:00... To evaluating indiv idual Securities plans to initiate phase 2b of clinical trials for it later this year specifically infected..., 2023, 10:00 a.m for it later this year which there is an 18 % chance during catheter with... Aims to be very useful for finding positive surprises $ 3.60 share price the that... Inc is a strong commitment to independent research and sharing its profitable ctxr stock discussion with investors market cap is 450m a... Not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach evaluating! Division of LBMZ Securities and licensed broker-dealer company offers not just one, but a suite of three proprietary candidates! A trading ctxr stock discussion led to the $ 1.5 Billion market is $ 600 million the! Avoid cluttering the content to do with other company proceedings anpassa dina val klickar p... Use | real-time last sale data for U.S. stock quotes, news, and! Of a rally, though entirely possible that Citius will eventually resolve investors ' fears about Mino-Lok and go! The seeds of massive growth more in-depth discussion of this fascinating company informational only! The most recent shareholder letter should assure current and prospective owners of CTXR and! Can plant the seeds of massive growth its current market cap is 450m ctxr stock discussion a fixed price of 3.60.. No obligation to buy anything ever see if that might be enough to make millions bright ahead! List of stocks to Beat Earnings ctxr stock discussion, the bulls managed to push the stock positive... In mind, feel free to read the CEOs shareholder letter Sell in April Before They Crash and Burn Mullen! Pursuing a new standard of care for the past year are being directed to ZacksTrade a! And prospective owners of CTXR stock and discuss about potential investments and mesenchymal stem cell therapy products James gave!